Benjamin Davis - AngioDynamics Senior Vice President Business Development
| ANGO Stock | USD 6.74 0.02 0.30% |
President
Mr. Benjamin H. Davis serves as a Senior Vice President, Business Development of the Company. Prior to joining AngioDynamics, Mr. Davis most recently was the Vice President of Business Integration at C.R. Bard, Inc. where he also served as the Divisional Head of Business Development from 20042013. Before joining C.R. Bard, Inc., Mr. Davis held the position of Chief Financial Officer and Treasurer at Axya Medical Inc. He holds a BS in Business Administration from Bryant College and Master in Business Administration in Finance from Bentley University Graduate School of Business. since 2015.
| Age | 60 |
| Tenure | 9 years |
| Address | 14 Plaza Drive, Latham, NY, United States, 12110 |
| Phone | 518 795 1400 |
| Web | https://www.angiodynamics.com |
AngioDynamics Management Efficiency
The company has return on total asset (ROA) of (0.0612) % which means that it has lost $0.0612 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7785) %, meaning that it created substantial loss on money invested by shareholders. AngioDynamics' management efficiency ratios could be used to measure how well AngioDynamics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Tangible Assets is likely to grow to -0.73. In addition to that, Return On Capital Employed is likely to grow to -0.41. At this time, AngioDynamics' Debt To Assets are very stable compared to the past year.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Eldon Schaffer | AptarGroup | 53 | |
| Joseph Wright | Merit Medical Systems | 54 | |
| Virginia Sanzone | ICU Medical | 49 | |
| William Burke | Haemonetics | 52 | |
| James Darecca | Haemonetics | 50 | |
| Xiangwei Gong | AptarGroup | 54 | |
| Jeffrey Kappler | Envista Holdings Corp | 41 | |
| Stewart Strong | Haemonetics | 57 | |
| Brian Andrews | The Cooper Companies, | 45 | |
| Pascal Bamford | Akoya Biosciences | N/A | |
| Howard Yu | Envista Holdings Corp | 51 | |
| Michelle Basil | Haemonetics | 52 | |
| Gael Touya | AptarGroup | 54 | |
| Jacqueline Scanlan | Haemonetics | 46 | |
| Robert Kuhn | AptarGroup | 62 | |
| Holly Sheffield | The Cooper Companies, | 53 | |
| Daniel Woolson | ICU Medical | 47 | |
| Daniel McBride | The Cooper Companies, | 56 | |
| Anila Lingamneni | Haemonetics | 57 | |
| Hedi Tlili | AptarGroup | 48 | |
| Randal Golden | The Cooper Companies, | 57 | |
Management Performance
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.0612 |
AngioDynamics Leadership Team
Elected by the shareholders, the AngioDynamics' board of directors comprises two types of representatives: AngioDynamics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AngioDynamics. The board's role is to monitor AngioDynamics' management team and ensure that shareholders' interests are well served. AngioDynamics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AngioDynamics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Chad Campbell, Senior Vice President and General Manager, Vascular Access | ||
| Laura Piccinini, Senior International | ||
| David Helsel, Senior Vice President - Global Operations | ||
| Warren Nighan, Senior Vice President-Senior Vice President Quality & Regulatory Affairs | ||
| Scott Centea, Senior Therapies | ||
| James Clemmer, President CEO, Director | ||
| Richard Rosenzweig, Gen VP | ||
| Marna BronfenMoore, Senior Resources | ||
| Kim Seabury, Senior Vice President Information Technology | ||
| Juan Serna, Senior Affairs | ||
| Stephen Trowbridge, Sr. VP, General Counsel and Assistant Secretary | ||
| Saleem Cheeks, Vice Communications | ||
| Benjamin Davis, Senior Vice President Business Development |
AngioDynamics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AngioDynamics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.0612 | ||||
| Profit Margin | (0.83) % | ||||
| Operating Margin | (0.13) % | ||||
| Current Valuation | 223.67 M | ||||
| Shares Outstanding | 40.63 M | ||||
| Shares Owned By Insiders | 5.47 % | ||||
| Shares Owned By Institutions | 81.40 % | ||||
| Number Of Shares Shorted | 1.23 M | ||||
| Price To Earning | 7.90 X |
Pair Trading with AngioDynamics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AngioDynamics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AngioDynamics will appreciate offsetting losses from the drop in the long position's value.Moving against AngioDynamics Stock
The ability to find closely correlated positions to AngioDynamics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AngioDynamics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AngioDynamics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AngioDynamics to buy it.
The correlation of AngioDynamics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AngioDynamics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AngioDynamics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AngioDynamics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AngioDynamics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in AngioDynamics Stock, please use our How to Invest in AngioDynamics guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AngioDynamics. If investors know AngioDynamics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AngioDynamics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.05) | Revenue Per Share 7.249 | Quarterly Revenue Growth (0.14) | Return On Assets (0.06) | Return On Equity (0.78) |
The market value of AngioDynamics is measured differently than its book value, which is the value of AngioDynamics that is recorded on the company's balance sheet. Investors also form their own opinion of AngioDynamics' value that differs from its market value or its book value, called intrinsic value, which is AngioDynamics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AngioDynamics' market value can be influenced by many factors that don't directly affect AngioDynamics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AngioDynamics' value and its price as these two are different measures arrived at by different means. Investors typically determine if AngioDynamics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AngioDynamics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.